Montrose Capital is a privately held investment company focused on Public Markets Venture Capital.
Mark Tompkins Montrose Capital investment fund is organized as open investment funds that is a separate property without legal entity whose shareholders are entitled to a proportional part of the income of the Montrose Capital at any time have the right to require payment of shares that will withdraw from it. Open Investment Fund, or separate property without legal entity composed of joint funds collected by issuing a public sale of shares of the Mark Tompkins Montrose Capital, as well as property acquired by the investment of these funds, including income and rights arising from such property.Investment funds are a great opportunity for venture capital, where investors have entrusted their funds and specialized institutions - fund management investment funds. The money collected through the sale of shares in the Mark Tompkins Montrose Capital, and the company will invest the same in accordance with the provisions of law, the Prospectus and the Articles of Incorporation. The Fund is owned by the holders. Owners of shares entitled to a proportional part of the income of the Fund, as at any time to require payment of the and thus withdraw from the fund.Investors in the fund may be domestic and / or foreign, physical and / or legal entities. The investment objective of Mark Tompkins Montrose Capital is to increase the value of the property, achieving steady growth in the value of the share and the high level of security for investment.For the realization of the investment objective, the Mark Tompkins intends to invest the assets of Montrose Capital primarily in market instruments money (deposits) and low-risk portfolio of debt securities.In the process of asset management company will implement its huge experience with tradition of safe and conservative investment process.
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Jun 8, 2016
Miramar Labs
|
Series Unknown | — | Health Care | — |
Jul 24, 2015
ViewRay
|
Post-IPO Equity | $26.70M | Biotechnology | — |